- Recommendation ID
- NG191/2
- Question
What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?
- Any explanatory notes
(if applicable) Suggested PICO (Population, Intervention, Comparator, Outcome)
P: patients 16 years and over who have been discharged after treatment for COVID-19 pneumonia
I: extended (2 to 6 weeks) pharmacological VTE prophylaxis with standard-dose:
• low molecular weight heparins
• unfractionated heparins
• fondaparinux sodium
• direct-acting anticoagulant
• vitamin K antagonistsC: no extended pharmacological VTE prophylaxis
O:
• incidence of VTE
• mortality (all-cause, inpatient, COVID-19 related)
• serious adverse events such as major bleeding or admission to hospital
Source guidance details
- Comes from guidance
- COVID-19 rapid guideline: managing COVID-19
- Number
- NG191
- Date issued
- March 2021
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 30/06/2021 |